SSI Strategy read six Western pharma partnering forms including Merck, Novartis, Pfizer, Sanofi, BMS, and J&J field by field.
Public source
Publisher name
Public post
We read six Western pharma partnering forms — Merck, Novartis, Pfizer, Sanofi, BMS, J&J — field by field. Not one has a box for how a molecule was discovered. If your en…
Company
SSI Strategy
Building Better Biotechs
- Industry
- Business Consulting and Services
- Location
- Parsippany, US
- Company size
- 51–200 employees
About SSI Strategy
At SSI Strategy, we're strategic partners deeply invested in our clients' success. We offer a unique, adaptive approach to supporting biotech companies, integrating business acumen with deep expertise in Clinical Development & Operations, Regulatory affairs, Pharmacovigilance, Medical Affairs, Quality and more. Our agile skills and resources model allows us to adapt to your specific needs, working as an embedded team within your organization. We complement your existing teams, scaling specialized skill sets up and down as needed, while equipping them with the tools and resources to operate at peak performance. By fostering the organization you want to build, we position your full-time employees to be more successful and effective in their strengths. As your needs evolve, so does our support. We offer deep expertise, strategic insight, and a comprehensive range of services to help you navigate the challenges of bringing a therapeutic from concept to commercialization. Our mission is clear: Build better biotechs through seamless collaboration, informed decision-making, and accelerated progress.
See moreLatest activity
Latest activity from SSI Strategy
4 signals
Presence & Recognition
SSI Strategy is hosting a strong line-up of events in Boston, San Diego, Madrid, and Milan for the rest of 2026.
Research & Knowledge
SSI Strategy published a new article in Frontiers in Medicine examining New Approach Methodologies (NAMs) from scientific, regulatory, and strategic perspectives.
Presence & Recognition
SSI Strategy attended the ESC Congress event in 2026.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Simon-Kucher
Simon-Kucher published an article examining how biotechs weigh access, speed, investment, and control to choose the right path to commercialization and make limited resources work harder.
Research & Knowledge
CELL'ECTIV Consulting
CELL'ECTIV Consulting published research showing that in H1 2026, 63% of biopharma M&A deals involved early- or mid-stage assets, versus 39% in 2025.
Research & Knowledge
Best Practices, LLC
Best Practices, LLC benchmarked research across 22 biopharma leaders found that 71% of Market Access leaders rate payer relationship management as highly effective.
Research & Knowledge
Curatio Advisors
Curatio Advisors analyzed late-stage, self-administered New Molecular Entities (NMEs) using BioLenz to find a mix of 62% Specialty, 28% Tweener, and 9% Retail.
Research & Knowledge
Prescient